700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Allergic rhinitis (AR) is a common, frequently occurring disease with increasing incidences every year. House dust mite is one of the common indoor allergens that causes allergic rhinitis. So this study was aimed to evaluate the efficacy and safety of Allergopharma house dust mite vaccine in the treatment of allergic rhinitis. A case self-control method was used to compare the total symptom using visual analog scale (VAS), nasal symptom score, as well as medication changes in 68 cases of patients with house dust mite-induced allergic rhinitis before and after receiving one year of immunotherapy. Out of 68 patients, 55 completed immunotherapy. After treatment, the total symptom VAS and nasal symptom score of 55 patients were significantly reduced compared with before treatment (P<0.01), and medication dosage was also lowered. Among a total of 1683 injections, local adverse reactions appeared 134 times, and mild systemic adverse reactions 17 times. However, no fatal systemic adverse reaction was observed. Allergopharma house dust mite vaccine is an effective and safe method of treatment for house dust mite-induced allergic rhinitis.
House dust mite, Allergic rhinitis, Immunotherapy, Allergopharma house dust mite vaccine